We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+37.48%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$2.6B
AUM Growth
+$619M
Cap. Flow
+$158M
Cap. Flow %
6.08%
Top 10 Hldgs %
36.7%
Holding
210
New
10
Increased
28
Reduced
33
Closed
16

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$46M
2
NKE icon
Nike
NKE
+$37.3M
3
PGEN icon
Precigen
PGEN
+$35M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$29.3M
5
PTCT icon
PTC Therapeutics
PTCT
+$20.8M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$38.2M
2
BA icon
Boeing
BA
+$23.1M
3
MTD icon
Mettler-Toledo International
MTD
+$22M
4
CRGX
CARGO Therapeutics
CRGX
+$12.6M
5
ELAN icon
Elanco Animal Health
ELAN
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.95%
2 Consumer Discretionary 2.06%
3 Technology 1.19%
4 Communication Services 0.91%
5 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPS
51
Compass Pathways
CMPS
$1.83B
$12.6M 0.49%
2,200,000
+900,000
+69% +$4.04M
BABA icon
52
Alibaba
BABA
$308B
$12.5M 0.48%
70,000
– –
ARVN icon
53
Arvinas
ARVN
$572M
$11.9M 0.46%
1,393,800
– –
STOK icon
54
Stoke Therapeutics
STOK
$2.11B
$11.8M 0.45%
500,000
– –
VNDA icon
55
Vanda Pharmaceuticals
VNDA
$302M
$11.7M 0.45%
2,353,307
– –
SRPT icon
56
Sarepta Therapeutics
SRPT
$1.77B
$11.6M 0.45%
600,000
+179,700
+43% +$3.2M
AZN icon
57
AstraZeneca
AZN
$250B
$11.5M 0.44%
75,000
– –
SMMT icon
58
Summit Therapeutics
SMMT
$11.1B
$11.4M 0.44%
550,000
+300,000
+120% +$7.28M
IDYA icon
59
IDEAYA Biosciences
IDYA
$3.56B
$10.9M 0.42%
+400,000
New +$9.67M
TDOC icon
60
Teladoc Health
TDOC
$1.3B
$10.8M 0.42%
1,400,000
– –
PCVX icon
61
Vaxcyte
PCVX
$8.64B
$10.8M 0.42%
300,000
– –
HELP
62
Cybin Inc
HELP
$720M
$10.8M 0.41%
1,830,097
– –
WGS icon
63
GeneDx Holdings
WGS
$2.3B
$10.8M 0.41%
100,000
– –
DNTH icon
64
Dianthus Therapeutics
DNTH
$6.09B
$10.4M 0.4%
264,692
– –
IDXX icon
65
Idexx Laboratories
IDXX
$46.2B
$10.2M 0.39%
16,000
– –
VTYX
66
DELISTED
Ventyx Biosciences
VTYX
$9.64M 0.37%
3,100,000
– –
BIOA
67
BioAge Labs
BIOA
$538M
$9.41M 0.36%
1,600,000
– –
PLRX icon
68
Pliant Therapeutics
PLRX
$65M
$8.89M 0.34%
6,003,446
+3,446
+0.1% +$5.26K
BHC icon
69
Bausch Health
BHC
$2.34B
$8.38M 0.32%
1,300,000
+563,173
+76% +$3.85M
CHRS icon
70
Coherus Oncology
CHRS
$196M
$8.36M 0.32%
5,097,362
– –
CBIO
71
Crescent Biopharma
CBIO
$626M
$8.08M 0.31%
679,824
+629,672
+1,256% +$8.35M
ALT icon
72
Altimmune
ALT
$599M
$8.04M 0.31%
2,131,307
-618,693
-22% -$2.39M
APGE icon
73
Apogee Therapeutics
APGE
$10.2B
$7.95M 0.31%
200,000
– –
MRNA icon
74
Moderna
MRNA
$23.6B
$7.89M 0.3%
305,300
– –
BDTX icon
75
Black Diamond Therapeutics
BDTX
$112M
$7.85M 0.3%
2,070,209
– –
1 2
3
4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Tang Capital Management held 210 positions worth $2.6B, up 31% from $1.98B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Tang Capital Management deployed $158M of net new capital in Q3 2025, opening 10 new positions and adding to 28 existing holdings. Its largest new stake was Celcuity: 1,150,000 shares worth $56.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Boeing, an estimated $23.1M trimmed.

  • Tang Capital Management's largest Q3 2025 buy was Celcuity: 1,150,000 shares worth $56.8M.
  • Tang Capital Management added most to Nike in Q3 2025, an estimated $37.3M increase.
  • Tang Capital Management's biggest Q3 2025 reduction was Boeing, cutting an estimated $23.1M.
  • Tang Capital Management fully exited iTeos Therapeutics in Q3 2025, selling an estimated $38.2M.
  • Tang Capital Management's ten largest holdings make up 37% of its $2.6B portfolio in Q3 2025.
  • Tang Capital Management opened 10 new positions and closed 16 in Q3 2025.
  • Tang Capital Management's portfolio value rose 31% quarter-over-quarter to $2.6B.

Based on Tang Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.